The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Boĭko A.N.

KGBUZ "Krasnoiarskiĭ kraevoĭ Tsentr po profilaktike i bor'be so SPID i infektsionnymi zabolevaniiami"

Alifirova V.M.

Sibirskiĭ gosudarstvennyĭ meditsinskiĭ universitet, Tomsk, Russia

Efficacy, safety and tolerability of glatiramer acetate injections in dose 40 mg/ml in patients with relapsing-remitting multiple sclerosis

Authors:

Boĭko A.N., Alifirova V.M.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(11): 135‑139

DOI: 10.17116/jnevro2017117111135-139

Read: 894 times

Download PDF (RU)
Contact the author
Table of contents

EFFICACY, SAFETY AND TOLERABILITY OF GLATIRAMER ACETATE INJECTIONS IN DOSE 40 MG/ML IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS
EFFICACY, SAFETY AND TOLERABILITY OF GLATIRAMER ACETATE INJECTIONS IN DOSE 40 MG/ML IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS

To cite this article:

Boĭko AN, Alifirova VM. Efficacy, safety and tolerability of glatiramer acetate injections in dose 40 mg/ml in patients with relapsing-remitting multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(11):135‑139. (In Russ.)
https://doi.org/10.17116/jnevro2017117111135-139

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
A clinical case of X-linked adre­noleukodystrophy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):102-107
Cognitive impairment in patients with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73
Arti­ficial inte­lligence capa­bilities in multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):14-21
Mole­cular mechanisms of acute disseminated ence­phalomyelitis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):7-11
The role of mono­cytes in the immu­nopathogenesis of multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):23-27
Resu­lts of a 5-year project for the early diagnosis of multiple scle­rosis in first-line blood rela­tives (RADIRS program). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):28-33
Current epidemiology of MS with onset in childhood and adolescence (pediatric multiple scle­rosis). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):34-38
Features of the clinical course of multiple scle­rosis as a factor in persistent disa­bility. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):39-44
Quantitative analysis of cere­brospinal fluid flow in multiple scle­rosis patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):45-50
Expe­rience of using ribo­ciclib in the therapy of meta­static breast cancer in a regional onco­logical dispensary. P.A. Herzen Journal of Onco­logy. 2025;(3):89-93
Abstract:

The article presents the results of an international study on the efficacy and safety of glatiramer acetate (GA) (40 mg/ml administered 3 times a week) compared with placebo in patients with relapsing-remitting multiple sclerosis (RRMS). This study was conducted in 142 sites in 17 countries including Russia. In total, the study included 1404 patients with RRMS including 166 patients from Russia. Glatiramer acetate (40 mg/ml 3 times a week) demonstrated the high efficacy, safety and tolerability profile. In conclusion, glatiramer acetate GA in dose 40 mg/ml should be considered as a more convenient regimen for RRMS patients which can improve patients’ adherence to treatment and as a result, its efficacy.

Keywords:

multiple sclerosis
glatiramer acetate
efficacy
safety

Authors:

Boĭko A.N.

KGBUZ "Krasnoiarskiĭ kraevoĭ Tsentr po profilaktike i bor'be so SPID i infektsionnymi zabolevaniiami"

Alifirova V.M.

Sibirskiĭ gosudarstvennyĭ meditsinskiĭ universitet, Tomsk, Russia

Close metadata

References:

  1. Shmidt TE, Yakhno NN. Rasseyannyi skleroz. M. 2010. (In Russ.)
  2. Alifirova VM, Titova MA. Epidemiological characteristics of multiple sclerosis in Tomsk Region and their dynamics for last 30 years. Bulleten sibirskoy medicine. 2012;3:132-134. (In Russ.)
  3. Gusev EI, Zavalishin IA, Boiko AN. Rasseyannyi skleroz. M.: Real Taim; 2011. (In Russ.)
  4. Nicholas JM. Complex drugs and biologics: scientific and regulatory challenges for follow on products. Drug Inf J. 2012;46(2):197-206. https://doi.org/10.1177/0092861512437759
  5. Wolinsky JS, Borresen TE, Dietrich DW, Wynn D, Sidi Y, Steinerman JR, Knappertz V, Kolodny S, on behalf of the GLACIER Study Group. GLACIER. An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2015;4(4):370-376. https://doi.org/10.1016/j.msard.2015.06.005
  6. Carter NJ, Keating GM. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis. Drugs. 2010;70:1545-1577. https://doi.org/10.2165/11204560-000000000-00000
  7. Ford C, Goodman AD, Johnson K, Kachuck N, Lindsey JW, Lisak R, Luzzio C, Myers L, Panitch H, Preiningerova J, Pruitt A, Rose J, Rus H, Wolinsky J. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult Scler. 2010;16(3):342-350. https://doi.org/10.1177/1352458509358088
  8. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB, Vollmer T, Weiner LP, Wolinsky JS, Copolymer Multiple Sclerosis Study Group. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology. 1995;45(7):1268-1276. https://doi.org/10.1212/wnl.45.7.1268
  9. Boyko AN, Davydovskaya MV, Demina TL, Lashch NYu, Ovcharov VV, Popova EV, Popova NF, Romashkin AV, Boyko OV, Khachanova NV, Sharanova SN, Shchur SG, Gusev EI. Efficacy and tolerability of long-term using of glatimer acetate(copaxon): a 10 year-study in the Moscow Municipal Multiple Sclerosis center. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2012;112(2):2:86-92. (In Russ.)
  10. Comi G, Cohen JA, Arnold DL, Wynn D, Filippi M. Phase III dose-comparison study of glatiramer acetate for multiple sclerosis. Ann Neurol. 2011;69(1):75-82. https://doi.org/10.1002/ana.22316
  11. Boster AL, Ford CC, Neudorfer O, Gilgun-Sherki Y. Glatiramer acetate: long-term safety and efficacy in relapsing-remitting multiple sclerosis Expert Rev. Neurother. 2015;15(6):575-586. https://doi.org/10.1586/14737175.2015.1040768
  12. Dhib-Jalbut S. Mechanism of action of interferons and glatiramer acetate in multiple sclerosis. Neurology. 2002;58(4):3-9. https://doi.org/10.1212/wnl.58.8_suppl_4.s3
  13. Farina C, Weber MS, Meinl E, Wekerle H, Hohlfeld R. Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. Lancet Neurol. 2005;4(9):567-575. https://doi.org/10.1016/s1474-4422(05)70167-8
  14. Khan O, Rieckmann P, Boyko A, Selmaj K, Zivadinov R., GALA Study Group. Three times weekly glatiramer acetate in relapsing and remitting multiple sclerosis. Ann Neurol. 2013;73:705-713. https://doi.org/10.1002/ana.23938
  15. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of Neurology. 2011;69(2):292-302. https://doi.org/10.1002/ana.22366
  16. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology. 1983;33:1444-1452. https://doi.org/10.1212/wnl.33.11.1444
  17. McKeage K. Glatiramer acetate 40 mg/mL in relapsing-remitting multiple sclerosis: a review. CNS Drugs. 2015;29(I):5:425-432. https://doi.org/10.1007/s40263-015-0245-z
  18. Zivadinov R, Dwyer M, Barkay H, Steinerman JR, Knappertz V, Khan O. Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense «black holes»: a post hoc magnetic resonance imaging analysis. J Neurol. 2015;262(3):648-653. https://doi.org/10.1007/s00415-014-7616-0
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.